KAI1/CD82和MRP-1/CD9在膀胱移行细胞癌中的表达及临床意义

Le résumé fourni par la source

[Objective] To investigate expression of KAI1/CD82 and MRP-1/CD9 in transitional cell carcinoma of the bladder (TCCB) and its clinical significance. [Methods] Immunohistochemistry was used to detect KAI1/CD82 and MRP-1/CD9 protein expression in 52 TCCB specimens. Correlations of the expression of KAI1/CD82 and MRP-1/CD9 to clinicopathological factors were statistically analyzed. [Results] The positive rates of KAI1/CD82 and MRP-1/CD9 in transitional cell carcinoma of the bladder were 50% and 61.5%, respectively. MRP-1/CD9 and KAI1/CD82 expression was significantly associated with the pathological grade of TCCB (P＜0.05), but no correlation was found between MRP-l/CD9 or KAIl/CD82 expression and clinical stage of TCCB (P＞0.05). Furthermore, MRP-l/CD9 and KAIl/CD82 were expressed at lower level in recurrent TCCB samples than that of non-recurrent samples (P＜0.05). Meanwhile, the correlation between KAI1/CD82 expression and MRP-1/CD9 expression was statistically significant (r=0.316, P＜0.05). [Conclusions] KAI1ICD82 and MRP-1/CD9 may be important prognostic indicators and potentially useful for assessing the biological behaviors of transitional cell carcinoma of the bladder.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.